关于双膦酸盐用于骨质疏松症的研究优先事项:英国优先事项设定活动
本研究采用James Lind Alliance方法,从相关研究和国际临床指南中收集研究不确定性,由临床和公众利益相关者提炼为33个研究问题,并通过改良名义群体技术确定前10位优先研究问题,涉及静脉双膦酸盐一线治疗人群、最佳治疗时长、骨转换标志物在治疗间歇中的作用等。
要点
- 利益相关者将34个草案不确定性最终确定为33个研究问题。
- 前10位优先问题包括哪些人应首先接受静脉双膦酸盐一线治疗和最佳治疗时长。
- 优先事项涉及如何更好地实施指南以弥补照护差距、理解影响治疗选择和效果的患者因素以及优化长期照护。
核心结论
- 本研究首次报告了利益相关者认为在双膦酸盐骨质疏松治疗 regimen 研究中重要的主题,这些发现对解决照护差距的实施研究和医疗专业人员教育具有意义。
研究设计与样本
- 采用基于James Lind Alliance方法学的三步法识别和优先排序研究问题,研究不确定性来自一个关于双膦酸盐 regimen 的大型相关研究项目以及近期发表的国际临床指南,临床和公众利益相关者将不确定性列表提炼为研究问题,第三步使用改良名义群体技术对问题进行优先排序。
主要发现
- 利益相关者将34个草案不确定性最终确定为33个研究问题。
- 前10位包括关于哪些人应首先接受静脉双膦酸盐一线治疗(第1位)、最佳治疗时长(第2位)、骨转换标志物在治疗间歇中的作用(第3位)等问题。
关键数值与推荐
- 前10位研究问题依次为:哪些人应首先接受静脉双膦酸盐一线治疗(1);最佳治疗时长(2);骨转换标志物在治疗间歇中的作用(3);支持患者药物优化需求(4);支持基层医疗从业者关于双膦酸盐的需求(5);比较社区与医院环境下给予唑来膦酸(6);确保符合质量标准(7);长期照护模式(8);50岁以下人群的最佳双膦酸盐(9);支持患者关于双膦酸盐的决策(10)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Worldwide, many people who would benefit from osteoporosis drugs are not offered or receiving them, resulting in an osteoporosis care gap. Adherence with bisphosphonates is particularly low. This study aimed to identify stakeholder research priorities relating to bisphosphonate treatment regimens for prevention of osteoporotic fractures. METHODS: A three-step approach based on the James Lind Alliance methodology for identification and prioritisation of research questions was used. Research uncertainties were gathered from a large programme of related research studies about bisphosphonate regimens and from recent published international clinical guidelines. Clinical and public stakeholders refined the list of uncertainties into research questions. The third step prioritised the questions using a modified nominal group technique. RESULTS: In total, 34 draft uncertainties were finalised into 33 research questions by stakeholders. The top 10 includes questions relating to which people should be offered intravenous bisphosphonates first line (1); optimal duration of treatment (2); the role of bone turnover markers in treatment breaks (3); support patient need for medicine optimisation (4); support primary care practitioner need regarding bisphosphonates (5); comparing zoledronate given in community vs hospital settings (6); ensuring quality standards are met (7); the long-term model of care (8); best bisphosphonate for people aged under 50 (9); and supporting patient decision-making about bisphosphonates (10). CONCLUSION: This study reports, for the first time, topics of importance to stakeholders in the research of bisphosphonate osteoporosis treatment regimens. These findings have implications for research into implementation to address the care gap and education of healthcare professionals. Using James Lind Alliance methodology, this study reports prioritised topics of importance to stakeholders in the research of bisphosphonate treatment in osteoporosis. The priorities address how to better implement guidelines to address the care gap, understanding patient factors influencing treatment selection and effectiveness, and how to optimise long-term care.
引用
- Paskins Z, Moult A, Corp N, et al. Research priorities regarding the use of bisphosphonates for osteoporosis: a UK priority setting exercise. Osteoporos Int. 2023. PMID: 37294333. doi:10.1007/s00198-023-06806-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。